SCHEMBL6046277

SCHEMBL6046277

c1ccc2c(c1)NCCO2.c1ccc2c(c1)OCCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.58
ICAM1 P05362 1/20 0.58
ITGAL P20701 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 3/20 0.52
CRHBP P24387 2/20 0.52
CRHR2 Q13324 2/20 0.52
HTT P42858 2/20 0.52
GAA P10253 3/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 1/20 0.52
KEAP1 Q14145 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
BRD4 O60885 1/20 0.40
NISCH Q9Y2I1 2/20 0.39
ADRB1 P08588 1/20 0.39
GRM5 P41594 3/20 0.38
PDE3B Q13370 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8942627 0.96 GAA (0.55) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL871099 0.96 GAA (0.55) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL88894 0.96 GAA (0.55) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL56313 0.96 GAA (0.55) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL27373511 0.94 GAA (0.53) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL12388067 0.90 SMN1; SMN2 (0.63) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL15479701 0.88 SMN1; SMN2 (0.59) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2315177 0.88 SMN1; SMN2 (0.59) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2316918 0.88 SMN1; SMN2 (0.59) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL8521592 0.88 SMN1; SMN2 (0.59) ITGB2ICAM1ITGALSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071180-B2 Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases BIOVITRUM AB (SE) 2006-07-04 US disclosed